Literature DB >> 7329898

Tinnitus in a patient with beta-thalassaemia intermedia on long-term treatment with desferrioxamine.

M N Marsh, I B Holbrook, C Clark, J L Shaffer.   

Abstract

A women with beta-thalassemia intermedia, and iron overload following many years' treatment with oral iron, was treated with subcutaneous desferrioxamine. During the course of this treatment she developed tinnitus, which was considered to be a rare complication of the use of this chelating agent. The mechanism of this effect is not understood.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7329898      PMCID： PMC2426146          DOI： 10.1136/pgmj.57.671.582

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  9 in total

1.  Continuous subcutaenous administration of deferoxamine in patients with iron overload.

Authors:  R D Propper; B Cooper; R R Rufo; A W Nienhuis; W F Anderson; H F Bunn; A Rosenthal; D G Nathan
Journal:  N Engl J Med       Date:  1977-08-25       Impact factor: 91.245

Review 2.  Advances in the use of iron-chelating agents for the treatment of iron overload.

Authors:  B Modell
Journal:  Prog Hematol       Date:  1979

3.  Long-term desferrioxamine therapy in thalassemia.

Authors:  C B Modell; J Beck
Journal:  Ann N Y Acad Sci       Date:  1974       Impact factor: 5.691

4.  Drug toxicity of the inner ear.

Authors:  R L Hybels
Journal:  Med Clin North Am       Date:  1979-03       Impact factor: 5.456

5.  Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload.

Authors:  M A Hussain; N Green; D M Flynn; S Hussein; A V Hoffbrand
Journal:  Lancet       Date:  1976-12-11       Impact factor: 79.321

6.  Computed tomography, ultrasound, and cholestatic jaundice.

Authors:  A Morris; R A Fawcitt; R Wood; W S Forbes; I Isherwood; M N Marsh
Journal:  Gut       Date:  1978-08       Impact factor: 23.059

7.  Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine.

Authors:  M A Hussain; N Green; D M Flynn; A V Hoffbrand
Journal:  Lancet       Date:  1977-05-07       Impact factor: 79.321

8.  Clinical trial of desferrioxamine entrapped in red cell ghosts.

Authors:  R Green; J Lamon; D Curran
Journal:  Lancet       Date:  1980-08-16       Impact factor: 79.321

9.  Iron absorption in iron-loading anaemias: Effect of subcutaneous desferrioxamine infusions.

Authors:  M J Pippard; S T Callender; G T Warner; D J Weatherall
Journal:  Lancet       Date:  1977-10-08       Impact factor: 79.321
  9 in total
  2 in total

1.  Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA.

Authors:  B Wonke; A V Hoffbrand; M Aldouri; D Wickens; D Flynn; M Stearns; P Warner
Journal:  Arch Dis Child       Date:  1989-01       Impact factor: 3.791

Review 2.  Hearing Loss in Beta-Thalassemia: Systematic Review.

Authors:  Immacolata Tartaglione; Roberta Carfora; Davide Brotto; Maria Rosaria Barillari; Giuseppe Costa; Silverio Perrotta; Renzo Manara
Journal:  J Clin Med       Date:  2021-12-25       Impact factor: 4.241
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.